EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Bryan P Schneider iD, Fengmin Zhao, Tarah J Ballinger iD, Sofia F Garcia iD, Fei Shen iD, Shamsuddin Virani, David Cella iD, Casey Bales iD, Guanglong Jiang iD, Lisa Hayes, Nadia Miller, Jayanthi Srinivasiah und 12 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00526 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Bryan P Schneider und 23 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Hauptthemen laut MEDLINE: Breast Neoplasms, Peripheral Nervous System Diseases, Paclitaxel, Docetaxel. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Black women experience higher rates of taxane-induced peripheral neuropathy (TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for early-stage breast cancer, leading to more dose reductions and higher recurrence rates. EAZ171 aimed to prospectively validate germline predictors of TIPN and compare rates of TIPN and dose reductions in Black women receiving (neo)adjuvant once weekly paclitaxel and once every 3 weeks docetaxel for early-stage breast cancer. METHODS Women with early-stage breast cancer who self-identified as Black and had intended to receive (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel were eligible, with planned accrual to 120 patients in each arm. Genotyping was performed to determine germline neuropathy risk. Grade 2-4 TIPN by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 was compared between high- versus low-risk genotypes and between once weekly paclitaxel versus once every 3 weeks docetaxel within 1 year. Patient-rated TIPN and patient-reported outcomes were compared using patient-reported outcome (PRO)–CTCAE and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity. RESULTS Two hundred and forty of 249 enrolled patients had genotype data, and 91 of 117 (77.8%) receiving once weekly paclitaxel and 87 of 118 (73.7%) receiving once every 3 weeks docetaxel were classified as high-risk. Physician-reported grade 2-4 TIPN was not significantly different in high- versus low-risk genotype groups with once weekly paclitaxel (47% v 35%; P = .27) or with once every 3 weeks docetaxel (28% v 19%; P = .47). Grade 2-4 TIPN was significantly higher in the once weekly paclitaxel versus once every 3 weeks docetaxel arm by both physician-rated CTCAE (45% v 29%; P = .02) and PRO-CTCAE (40% v 24%; P = .03). Patients receiving once weekly paclitaxel required more dose reductions because of TIPN (28% v 9%; P < .001) or any cause (39% v 25%; P = .02). CONCLUSION Germline variation did not predict risk of TIPN in Black women receiving (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel. Once weekly paclitaxel was associated with significantly more grade 2-4 TIPN and required more dose reductions than once every 3 weeks docetaxel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPeripheral Nervous System DiseasesPaclitaxelDocetaxelBlack or African AmericanHumansFemaleMiddle AgedProspective StudiesAdultAgedTaxoidsNeoplasm StagingGerm-Line MutationBridged-Ring Compounds

Substanzen

PaclitaxelDocetaxelTaxoidsBridged-Ring Compoundstaxane

Autor:innen und Institutionen

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
  • Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington, WI.
  • Pink-4-Ever Ending Disparities, Indianapolis, IN.
  • Georgia NCORP, Decatur, GA.

ORCID-Profile: Bryan P Schneider, Tarah J Ballinger, Sofia F Garcia, Fei Shen, David Cella, Casey Bales, Guanglong Jiang, Erica M Stringer-Reasor, Ami Chitalia, Andrew A Davis, Melissa A Simon, Angela DeMichele, Kathy D Miller, Joseph A Sparano, Lynne I Wagner, Antonio C Wolff

Förderung

  • NCI NIH HHS

Zitieren

APA

Schneider, B. P., Zhao, F., Ballinger, T. J., Garcia, S. F., Shen, F., Virani, S., Cella, D., Bales, C., Jiang, G., Hayes, L., Miller, N., Srinivasiah, J., Stringer-Reasor, E. M., Chitalia, A., Davis, A. A., Makower, D. F., Incorvati, J., Simon, M. A., Mitchell, E. P., …, & Wolff, A. C. (2024). ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00526

Vancouver

Schneider BP, Zhao F, Ballinger TJ, Garcia SF, Shen F, Virani S, et al. ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00526

BibTeX
@article{Schneider2024,
  author = {Schneider, Bryan P and Zhao, Fengmin and Ballinger, Tarah J and Garcia, Sofia F and Shen, Fei and Virani, Shamsuddin and Cella, David and Bales, Casey and Jiang, Guanglong and Hayes, Lisa and Miller, Nadia and Srinivasiah, Jayanthi and Stringer-Reasor, Erica M and Chitalia, Ami and Davis, Andrew A and Makower, Della F and Incorvati, Jason and Simon, Melissa A and Mitchell, Edith P and DeMichele, Angela and Miller, Kathy D and Sparano, Joseph A and Wagner, Lynne I and Wolff, Antonio C},
  title = {ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00526}
}
Kostenlos starten →